Among adults with type 2 diabetes (T2D) initiating second-line antidiabetic medication (ADM) therapy, the short-term cardiovascular (CV) outcomes of glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, and dipeptidyl peptidase 4 (DPP-4) inhibitors were similar, a recent study found. The cohort study included 132,737 adults (aged 45-64 years) with T2D and examined the association of second-line ADM classes with major adverse CV events. Researchers found:
- GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors were associated with similar CV outcomes.
- Sulfonylureas and basal insulin were associated with comparatively higher CV risk.
- Clinicians may consider prescribing newer ADM classes more routinely after metformin.
O’Brien MJ, Karam SL, Wallia A, et al. Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes. JAMA Netw Open. 2018;1(8):e186125. doi:10.1001/jamanetworkopen.2018.6125.
This Week's Must Reads
Must Reads in Diabetes
Testosterone Therapy to Prevent T2D in Men, Diabetes Care; ePub 2019 Mar 18; Yassin, et al
Patterns of Diabetes Screening During Office Visits, J Am Board Fam Med; 2019 Mar-Apr; Shealy, et al
Muscular Strength and Incidence of Type 2 Diabetes, Mayo Clin Proc; ePub 2019 Mar 11; Wang, et al
Insulin Management in Patients with T2D, Lancet; ePub 2019 Feb 22; Bergenstal, et al